生物股份(600201.SH):子公司鴨傳染性漿膜炎二價滅活疫苗(1型SG4株+2型ZZY7株)獲獸藥產品批准文號批件
格隆匯2月9日丨生物股份(600201.SH)公佈,根據《獸藥管理條例》和《獸藥產品批准文號管理辦法》等有關規定,經農業農村部審查,准予金宇生物技術股份有限公司控股子公司遼寧益康生物股份有限公司(“遼寧益康”)生產鴨傳染性漿膜炎二價滅活疫苗(1型SG4株+2型ZZY7株),並核發獸藥產品批准文號。
上述產品由遼寧益康聯合中國農業大學等單位共同開展新獸藥註冊相關工作,於2013年1月29日獲得新獸藥註冊證書。截至目前,該產品研發投入金額為247萬元。
鴨傳染性漿膜炎是由鴨疫裏默氏桿菌引起的嚴重危害雛鴨的一種接觸性、急性或慢性敗血性傳染病,鴨只感染後發病率高達90%。由於鴨疫裏默氏桿菌血清型較多,且各血清型之間無交叉保護,給疫病防預帶來了較大困難。遼寧益康本次獲批的鴨傳染性漿膜炎二價滅活疫苗(1型SG4株+2型ZZY7株)採用國內流行的優勢血清型菌株,所製備的疫苗免疫譜廣,免疫原性強,安全性高,雛鴨免疫後無副反應,可產生良好的免疫效果,保障鴨只健康生長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.